Appropriatezza diagnostico-terapeutica in oncologia - Quaderni del ...

Ministero della Salute
Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant
therapy with paclitaxel followed by 5-fluorouracil, epirubicin,
and cyclophosphamide chemotherapy and concurrent
trastuzumab in human epidermal growth factor
receptor 2-positive operable breast cancer: an update of
the initial randomized study population and data of
additional patients treated with the same regimen. Clin
Cancer Res 2007; 13: 228-33
Coates AS, Keshaviah A, Thurlimann B, et al. Five
years of letrozole compared with tamoxifen as initial
adjuvant therapy for postmenopausal women with endocrine-responsive
early breast cancer: update of study
BIG 1-98. J Clin Oncol 2007; 25: 486-92
Coombs RC, Kilburn LS, Snowdon CF, et al. Survival
and safety of exemestane versus tamoxifen after 2-3 years’
tamoxifen treatment (Intergroup Exemestane Study): a
randomised controlled trial. Lancet 2007; 369: 559-70
Cuppone F, Bria E, Carlini P, et al. Taxanes as primary
chemotherapy for early breast cancer. Meta-analysis
of randomized trials. Cancer 2008; 113: 238-46
De Laurentiis M, Cancello G, D’Agostino D, et al.
Taxane-based combinations as adjuvant chemotherapy
of early breast cancer: a meta-analysis of randomized
trials. J Clin Oncol 2008; 26: 44-53
Early Breast Cancer Trialists’ Collaborative Group. Effects
of chemotherapy and hormonal therapy for early breast
cancer on recurrence and 15-year survival: an overview
of the randomised trials. Lancet 2005; 365: 1687-717
Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in
treatment of intraductal breast cancer: National Surgical
Adjuvant Breast and Bowel Project B-24 randomised
controlled trial. Lancet 1999; 353: 1993-2000
Fisher ER, Redmond C, Fisher B, et al. Pathologic
findings from the National Surgical Adjuvant Breast
and Bowel Projects (NSABP). Prognostic discriminants
for 8-year survival for node-negative invasive breast
cancer patients. Cancer 1990; 65 (Suppl. 9): 2121-8
Gianni L, Goldhirsch A, Gelber RD, et al. Update of
the HERA trial and the role of 1 year trastuzumab as
adjuvant therapy for breast cancer. The Breast 2009;
18 (Suppl. 1): S11 (abstract S25)
Gianni L, Semiglazov V, Manikhas GM, et al. Neoadjuvant
trastuzumab in locally advanced breast cancer
(NOAH): antitumour and safety analysis. J Clin Oncol
2007; 25 (Suppl.): 10S (abstract 532)
Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine
therapy plus zoledronic acid in premenopausal
breast cancer. N Engl J Med 2009; 360: 679-91
Goss PE, Ingle JN, Martino S, et al. Randomized trial
of letrozole following tamoxifen as estended adjuvant
therapy in receptor-positive breast cancer: updated
findings from NCIC CTG MA:17. J Natl Cancer Inst
2005; 97: 1262-71
Hadji P, Body JJ, Apro MS, et al. Practical guidance
for the management of aromatase inhibitor-associated
bone loss. Ann Oncol 2008; 19: 1407-16
Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase
inhibitors versus tamoxifen as adjuvant therapy for
postmenopausal women with estrogen receptor positive
breast cancer: meta-analysis of randomized trials of
monotherapy and switching strategies. Cancer Res
2009; 69: 12
Jakesz R, Gnant M, Griel R, et al. Tamoxifen and
anastrozole as a sequencing strategy in postmenopausal
women with hormone-responsive early breast cancer:
updated data from the Austrian breast and colorectal
cancer study group trial 8. Cancer Res 2009; 69: 14
Joensuu H, Bono P, Kataja V, et al. Update of the
FINHER trial based on 5 year of follow-up. The Breast
2009; 18 (Suppl. 1): S10 (abstract S24)
Jones SE, Seynaeve C, Hasenburg A, et al. Results of the
first planned analysis of the TEAM (tamoxifen exemestane
adjuvant multinational) prospective randomized
phase III trial in hormone sensitive postmenopausal early
breast cancer. San Antonio Breast Cancer Symposium
2008 (abstract 15)
Kaufmann M, Jonat W, Hilfrich J, et al. Improved
overall survival in postmenopausal women with early
breast cancer after anastrozole initiated after treatment
with tamoxifen compared with continued tamoxife:
the ARNO 95 Study. J Clin Oncol 2007; 25: 2664-70
44